Opinion|Videos|January 3, 2025
Treatment Goals and Unmet Needs in R/R AML
Panelists discuss how achieving responses with second-line treatment options after venetoclax-based regimens remains challenging, and explore strategies for bridging therapy to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients who relapse post venetoclax while also addressing the evolving management of patients following transplant.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on your clinical experience with the difficulty achieving responses with the currently available second line and beyond treatment options after patients are treated with venetoclax plus azacitidine (or decitabine).
- How do current therapies meet the needs of patients post-venetoclax failure?
- How often are you able to bring your patients to allo-HSCT once they relapse post venetoclax? How are utilizing the currently available R/R options as bridging therapy to allo-HSCT?
- How are you managing patients following a transplant? Do you see this changing in the future?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
DESTINY-Breast05 Safety Analysis Clarifies ILD and Radiation Risks With T-DXd in HER2+ Breast Cancer
Charles E. Geyer, MD, discusses data from the DESTINY-Breast05 safety analysis evaluating ILD and radiation pneumonitis outcomes in HER2+ breast cancer.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
The selective ROCK2 inhibitor TDI01 generated organ-wide responses in previously treated moderate-to-severe chronic graft-versus-host disease, with the 400-mg dose performing best.
The FDA approved rusfertide for the treatment of patients with polycythemia vera.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
The phase 3 DAWN-303 trial is evaluating the oral KRAS G12D inhibitor INCB161734 in previously untreated, KRAS G12D–mutated metastatic PDAC.
Richard K. and Nancy K. Lubin have made a $35 million gift to Dana-Farber Cancer Institute’s Future of Cancer Care Fund.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Rusfertide for Polycythemia Vera
2
The OncFive: Top Oncology Articles for the Week of 8/23
3
DAWN-303 Trial Set to Advance INCB161734 in First-Line KRAS G12D–Mutated Metastatic Pancreatic Cancer
4
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
5